

Supplementary Tables

Supplementary Table S1. Neuroblastoma patient cohort clinical information

TMA	GeoMx	CODEX	ID	TMAMap	Patient ID	Treatment	Staging	Age at diagnosis Years	Age diagnosis month	Histology	MYCN amplification	Risk group	Gender	Follow Up Months	Overall Survival Months	Overall Survival Years	Death	Residual recurrence	Stroma	Schwann cells	Index M:C	Shimada
TMA1	Y	Y	1	TMA1_C1	06 2382	Pre-treatment	I	0.8	<12	Poorly differentiated	N	Low/Intermediate	M	36	36	3	No	No	Poor	Absent	3%	Favorable
TMA1	Y	Y	2	TMA1_D1	06 023 (1)	Pre-treatment	II	0.1	<12	Poorly differentiated	N	Low	M	72	72	6	No	No	Poor	Absent	3%	Favorable
TMA1	N	Y	3	TMA1_E1	07 1793	Pre-treatment	IV	0.4	<12	Poorly differentiated	Unknown	Unknown	M	12	12	1	No	No				
TMA1	Y	Y	4	TMA1_B2	12 2386 (1)	Pre-treatment	III	1.3	12 - 18	Poorly differentiated	Unknown	Unknown	M	24	24	2	No	Yes	Poor	Absent	>4%	Unfavorable
TMA1	N	Y	5	TMA1_C2	09 770	Pre-treatment	IV	4.3	>18	Poorly differentiated	N	High	M	24	24	2	Yes	Yes				
TMA1	Y	Y	6	TMA1_D2	10 2024	Pre-treatment	IV	1.5	>18	Poorly differentiated	Unknown	High	F	7	7	0	Yes	No	Poor	Absent	>4%	Unfavorable
TMA1	Y	Y	7	TMA1_E2	09 2833	Pre-treatment	IV	6.0	>18	Poorly differentiated	Y	High	F	12	12	1	Yes	Yes	Poor	Absent	>4%	Unfavorable
TMA1	Y	Y	8	TMA1_A3	13 0264 (1.1)	Pre-treatment	IV	0.0	<12	Poorly differentiated	N	Low/Intermediate	M	48	48	4	No	No	Poor	Absent	3%	Favorable
TMA1	N	N	9	TMA1_B3	12 759 (1)	Pre-treatment	IV	0.4	<12	Poorly differentiated	N	Low/Intermediate	M	12	12	1	Yes	Yes	Poor	Absent	>4%	Unfavorable
TMA1	Y	Y	10	TMA1_C3	11 385 (1)	Pre-treatment	IV	2.0	>18	Poorly differentiated	Unknown	High	M	9	9	0	Yes	Yes	Poor	Absent	>4%	Unfavorable
TMA1	Y	Y	11	TMA1_D3	12 1813 (1)	Pre-treatment	IV	3.8	>18	Poorly differentiated	Unknown	High	M	12	12	1	Yes	Yes				Unfavorable
TMA1	N	Y	12	TMA1_E3	09 1231	Pre-treatment	IV	10.8	>18	Poorly differentiated	N	High	F	84	84	7	No	No	Poor	Absent	>4%	Unfavorable
TMA1	N	Y	13	TMA1_A4	05 2031	Pre-treatment	IV	2.3	>18	Poorly differentiated	Y	High	F	3	3	0	Yes	Yes	Poor	Absent	>4%	Unfavorable
TMA3	N	N	14	TMA3_A1	05 1585	Pre-treatment	IV	0.9	<12	Poorly differentiated	Y	High	F	120	120	10	No	Yes	Poor	Absent	>4%	Unfavorable
TMA3	N	N	15	TMA3_A2	05 2063 (2)	Pre-treatment	III	1.7	>18	Differentiating	N	Low/Intermediate	M	60	60	5	No	No				
TMA3	Y	Y	16	TMA3_D1	07 774	Pre-treatment	I	0.7	<12	Differentiating	N	Low	F	84	84	7	No	No	Poor	Absent	1%	Favorable
TMA3	Y	Y	17	TMA3_B2	08 963 (1)	Pre-treatment	I	1.1	12-18	Differentiating	N	Low	F	96	96	8	No	No	Rich	Absent	<1%	Favorable
TMA3	Y	Y	18	TMA3_E2	08 999 (2)	Pre-treatment	III	2.7	>18	Differentiating	N	Low/Intermediate	M	84	84	7	No	No	Poor	Absent	2%	Unfavorable
TMA3	Y	Y	19	TMA3_B1	09 1567	Pre-treatment	I	0.4	<12	Differentiating	N	Low	M	48	48	4	No	No	Poor	Absent	<1%	Favorable
TMA3	Y	Y	20	TMA3_D2	09 2258	Pre-treatment	II	0.8	<12	Differentiating	N	Low	F				No	No	Rich	Absent	<1%	Favorable
TMA3	Y	N	21	TMA3_C2	11 301 (1/2)	Pre-treatment	I	1.0	12-18	Differentiating	N	Low	M	60	60	5	No	No	Rich	Absent	<1%	Favorable
TMA3	Y	Y	22	TMA3_E1	11 534 (1)	Pre-treatment	I	0.4	<12	Differentiating	N	Low	F	36	36	3	No	No	Rich	Absent	<1%	Favorable
TMA3	Y	Y	23	TMA3_C1	13 0112 (2)	Pre-treatment	I	0.0	<12	Differentiating	N	Low	M	24	24	2	No	Unknown	Rich	Absent	5%	Unfavorable
TMA5	N	N	24	TMA5_A1	11B182	Pre-treatment	IV	4.3	>18	Poorly differentiated	N	High	M	12	12	1	Yes	Yes	Poor	Absent	>4%	Unfavorable
TMA5	Y	N	25	TMA5_B1	07B1385	Pre-treatment	IV	4.7	>18	Differentiating	N	High	F	72	72	6	Yes	Yes	Poor	Absent	1%	Unfavorable

TMA5	Y	Y	26	TMA5_C1	06B997	Pre-treatment	IV	4.0	>18	Poorly differentiated	N	High	M	36	36	3	Yes	Yes	Poor	Absent	>4%	Unfavorable
TMA5	Y	N	27	TMA5_D1	07B728	Pre-treatment	IV	2.7	>18	Poorly differentiated	Y	High	M	24	24	2	Yes	Yes	Poor	Absent	>4%	Unfavorable
TMA5	Y	Y	28	TMA5_B3	06B2326	Pre-treatment	III	0.7	<12	Poorly differentiated	Y	High	M	12	12	1	Yes	Yes	Poor	Absent	>4%	Unfavorable
TMA5	Y	Y	29	TMA5_C3	11B3237	Pre-treatment	IV	2.0	>18	Poorly differentiated	Unknown	High	F	24	24	2	Yes	Yes	Poor	Absent	>4%	Unfavorable
TMA5	Y	N	30	TMA5_D3	10B1638	Pre-treatment	IV	0.0	<12	Poorly differentiated	Y	High	M	36	36	3	Yes	Yes	Poor	Absent	>4%	Unfavorable
TMA5	N	Y	31	TMA5_E3	12B2579	Pre-treatment	II	1.3	12-18	Poorly differentiated	N	Low/Intermediate	F	20	20	2	No	Unknown	Poor	Absent	>4%	Unfavorable
TMA5	N	Y	32	TMA5_A2	11B2791	Post-treatment	IV	4.3	>18	Poorly differentiated	N	High	M	12	12	1	Yes	Yes	Poor	Absent	>4%	Unfavorable
TMA5	Y	Y	33	TMA5_B2	08B1816	Post-treatment	IV	4.7	>18	Differentiating	N	High	F	72	72	6	Yes	Yes	Poor	Absent	1%	Unfavorable
TMA5	Y	Y	34	TMA5_C2	07B370	Post-treatment	IV	4.0	>18	Poorly differentiated	N	High	M	36	36	3	Yes	Yes	Poor	Absent	>4%	Unfavorable
TMA5	Y	Y	35	TMA5_E2	12B69	Post-treatment	IV	0.1	<12	Poorly differentiated	Unknown	Unknown	M	60	60	5	No	No	Poor	Absent	>4%	Unfavorable
TMA5	Y	Y	36	TMA5_B4	07B1514	Post-treatment	III	0.7	<12	Poorly differentiated	Y	High	M	12	12	1	Yes	Yes	Poor	Absent	>4%	Unfavorable
TMA5	Y	N	37	TMA5_D4	11B363	Post-treatment	IV	0.0	<12	Poorly differentiated	Y	High	M	36	36	3	Yes	Yes	Poor	Absent	>4%	Unfavorable
TMA5	N	Y	38	TMA5_E4	13B355	Post-treatment	II	1.3	12-18	Poorly differentiated	N	Low/Intermediate	F	20	20	2	No	Unknown	Poor	Absent	>4%	Unfavorable
Note: Y: Yes; N: No																						